Metformin sensitizes clonally evolved imatinib–geldanamycin-resistant CML models through AMPK–HSF1 and AMPK–RUNX1 signaling
Cell Death · 2026-07 · 2 (3) · 100023
DOI: 10.1016/j.celld.2026.100023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Death, 2026-07. Verfasst von Meher Bolisetti Gayatri und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: India Ministry of Science & Technology Department of Biotechnology, Department of Science and Technology, Ministry of Science and Technology, India, University of Hyderabad.
Abstract (Originalsprache)
Multidrug resistance is one of the common features of the blast crisis (BC) phase of chronic myeloid leukemia (CML). One of the major pathways involved in drug resistance is the activation of the JAK2-STAT3 axis and the HSF1-mediated heat shock response. In this study, we investigated the role of metformin in sensitizing drug-resistant cells by modulating the pathways via the AMPK substrates HSF1 and RUNX1. Our experiments using clonally derived imatinib- and geldanamycin-dual-resistant K562 cell lines demonstrated that AMPK-mediated phosphorylation primes HSF-1 for ubiquitination, thereby inhibiting activation of the heat shock response. Additionally, AMPK phosphorylation inhibited the nuclear localization of RUNX1, increasing SOCS3 expression and leading to the loss of STAT3 activation. The data support the conclusion that metformin sensitizes resistant CML models and patient-derived PBMCs and indicate an AMPK–HSF1/RUNX1-linked mechanism.
Förderung
- India Ministry of Science & Technology Department of Biotechnology
- Department of Science and Technology, Ministry of Science and Technology, India
- University of Hyderabad
Zitieren
APA
Gayatri, M. B., Behera, A., Kancha, R. K., Patchva, D., Velugonda, N., Gundeti, S., & Reddy, A. B. M. (2026). Metformin sensitizes clonally evolved imatinib–geldanamycin-resistant CML models through AMPK–HSF1 and AMPK–RUNX1 signaling. Cell Death, 2(3), 100023. https://doi.org/10.1016/j.celld.2026.100023
Vancouver
Gayatri MB, Behera A, Kancha RK, Patchva D, Velugonda N, Gundeti S, et al. Metformin sensitizes clonally evolved imatinib–geldanamycin-resistant CML models through AMPK–HSF1 and AMPK–RUNX1 signaling. Cell Death. 2026;2(3):100023. doi:10.1016/j.celld.2026.100023
BibTeX
@article{Gayatri2026,
author = {Gayatri, Meher Bolisetti and Behera, Abhayananda and Kancha, Rama Krishna and Patchva, Dorababu and Velugonda, Nagaraj and Gundeti, Sadasivudu and Reddy, Aramati Bindu Madhava},
title = {Metformin sensitizes clonally evolved imatinib–geldanamycin-resistant CML models through AMPK–HSF1 and AMPK–RUNX1 signaling},
journal = {Cell Death},
year = {2026},
volume = {2},
number = {3},
pages = {100023},
doi = {10.1016/j.celld.2026.100023}
}
EUVIMED